Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the effect of FYX-051 on cardiac repolarization
jRCT2080221352Phase 3
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of topiroxostat in gout, sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoint: Effect of FYX-051 on cardiac repolarization (QT/QTc interval).
02
Drugs
topiroxostat
03
Conditions
gout
Beyond the preview
Go deeper on jRCT2080221352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221352.